

EV 351 923 149 US: Express Mail Number

July 11, 2003: Date of Deposit

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Type of Application

Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, and James C. Marsters Jr.

Title:

1.

### **LFA-1 ANTAGONIST COMPOUNDS**

[]	This application is for an original, non-provisional application.

[]	This is a non-provisional application claiming priority to provisional application no.	, filed
	, the entire disclosure of which is hereby incorporated by reference.	

[x] This is a [] continuation-in-part [x] continuation- [] divisional application claiming priority under 35 U.S.C. § 120 to application Serial Number 09/994,546, filed November 26, 2001, and under 35 U.S.C. § 119(e) to provisional application Serial No. 60/253,682, filed November 28, 2000, the entire disclosures of which are hereby incorporated by reference.

# 2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)

113	pages	of	specification				
		ء۔	مأماسم				

- \_\_5\_\_ pages of claims \_\_1\_\_ page(s) of abstract
- 0 sheet(s) of drawings
  - [] formal [] informal



3.	Decl	aration or Oath
	_	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added) An executed declaration of the inventor(s) [] is enclosed [] will follow.
	<u>x</u>	(for Cont./Div. where inventorship is the same or inventor(s) being deleted) A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).
	_	(for Cont./Div. where inventor(s) being deleted) A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).
4.	Assi	gnment
		(for new and CIP applications) An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.
	x_	(for cont./div.) The prior application is assigned of record to Genentech, Inc.
5.	Ame	ndments (for continuation and divisional applications)
		Cancel in this application original claims _ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
		A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

## 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

		CLAIN	IS FOR FEE CA	LCULATION			
Number	Filed	Numb	er Extra	Rate	Basic Fee 37 CFR 1.16(a)		
					\$750.00		
Total Claims	23	- 20 =	3	X \$18.00	\$54.00		
Independent Claims	1	- 3=	0	X \$84.00	\$0.00		
	Multiple d	ependent claim	+ \$280.00	\$0.00			
			Fili	ing Fee Calculation	\$804.00		

## 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$804.00. A duplicate copy of this transmittal is enclosed.

## 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. <u>A duplicate copy of this transmittal is enclosed.</u>

## 9. Additional Papers Enclosed

- [x] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations and a copy of PCT Written Opinion.
- Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- A new Power of Attorney or authorization of agent.
- [x] Other: Copy of Limited Recognition Under 37 CFR 10.9(b)\*

10.	Maintenance	of	Copendency	of	Prior	Application	(for	continuation	and	divisional
applica	ations)									

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

	A petition, fee and/or response has been filed to extend the term in
	the pending prior application until
	A copy of the petition for extension of time in the <i>prior</i> application
	is attached.

## 11. Correspondence Address:

X Address all future communications to:

Attn: David W Evans

Respectfully submitted, GENENTECH, INC.

Date: July 11, 2003

By:

David/W/Evans

Red Nø. \*

Telephone No. (650) 225-1739

09157

PATENT TRADEMARK OFFICE

<sup>\*</sup>A copy of a document pursuant to 37 C.F.R. § 10.9(b) is attached as proof of the authorization of the above to prosecute the attached application. The original of this document is on file in the Office of Enrollment and Discipline.